Tezacitabine
Tezacitabine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Golytely, Polyethylene glycol 3350 electrolytes (discontinued: Co-lav, Colyte with flavor packs, Go-evac, Golytely, Osmoprep, Peg 3350 electrolytes, Peg-lyte, Polyethylene glycol 3350 electrolytes, Visicol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Polyethylene glycol 3350
+
Potassium chloride
+
Sodium bicarbonate
+
Sodium chloride
+
Sodium sulfate anhydrous
Sodium phosphate
+
dibasic
+
anhydrous
+
Sodium phosphate
+
monobasic
+
monohydrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OSMOPREP | Salix Pharmaceuticals | N-021892 DISCN | 2006-03-16 | 1 products, RLD |
| VISICOL | Salix Pharmaceuticals | N-021097 DISCN | 2000-09-21 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 28tak gum care tooth | unapproved drug other | 2018-07-17 |
| akten | New Drug Application | 2026-04-23 |
| alka seltzer | OTC monograph final | 2012-11-09 |
| alka seltzer original | OTC monograph not final | 2019-07-08 |
| alka-seltzer extra strength | C200263 | 2025-12-04 |
| alka-seltzer extra strength pain relief | C200263 | 2026-02-05 |
| alka-seltzer hangover relief | C200263 | 2025-10-16 |
| alka-seltzer heartburn | C200263 | 2025-12-04 |
| alka-seltzer heartburn and pain | C200263 | 2024-12-13 |
| alka-seltzer heartburn relief extra strength | C200263 | 2025-03-11 |
Show 96 more
Indications
FDA
EMA
Show 4 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
236 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | — | — | 1 | 1 | 1 | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 2 | — | 1 | — | 3 |
| Inflammation | D007249 | MP_0001845 | — | 1 | — | — | 1 | 1 | 3 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | 2 | 1 | 3 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | 1 | 1 | — | 3 |
| Colonoscopy | D003113 | — | — | — | — | — | 2 | 1 | 3 |
| Colonic neoplasms | D003110 | — | C18 | — | 1 | — | 1 | — | 2 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 1 | — | 1 | — | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 1 | 1 | 2 |
| Communicable diseases | D003141 | — | — | — | — | 1 | 1 | — | 2 |
Show 24 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 2 | 5 | 4 | — | — | 11 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 3 | 1 | — | 1 | 7 |
| Seizures | D012640 | — | G40.4 | 2 | — | 2 | — | — | 4 |
| Myoclonic epilepsies | D004831 | EFO_1001900 | G40.4 | — | 1 | 2 | — | — | 3 |
| Abdominal pain | D015746 | EFO_0003766 | R10.9 | — | — | 1 | — | 2 | 3 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 2 | 1 | — | — | 2 |
| Infantile spasms | D013036 | EFO_1000643 | G40.82 | — | — | 2 | — | — | 2 |
| Tuberous sclerosis | D014402 | — | Q85.1 | — | — | 2 | — | — | 2 |
| Lennox gastaut syndrome | D065768 | — | G40.81 | — | — | 2 | — | — | 2 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | — | 1 | 2 |
Show 34 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | 1 | — | — | 7 | 11 |
| Colorectal neoplasms | D015179 | — | — | 2 | 5 | — | — | 2 | 7 |
| Overweight | D050177 | — | E66.3 | — | 2 | — | — | 4 | 6 |
| Neoplasms | D009369 | — | C80 | 3 | 2 | — | — | 1 | 5 |
| Carcinoma | D002277 | — | C80.0 | 2 | 1 | — | — | 2 | 4 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 2 | — | — | 2 | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | — | 2 | 4 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 1 | — | — | — | 3 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 1 | — | — | 2 | 3 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | 2 | 3 |
Show 57 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | — | — | — | 1 | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | 2 | 3 |
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | — | — | — | — | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | — | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | 2 | — | — | — | — | 2 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | — | — | — | 1 | 2 |
| Alopecia | D000505 | — | L64 | 1 | — | — | — | 1 | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
Show 39 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fatigue | D005221 | — | R53.83 | — | — | — | — | 5 | 5 |
| Physical fitness | D010809 | — | — | — | — | — | — | 4 | 4 |
| Hyperglycemia | D006943 | — | R73.9 | — | — | — | — | 3 | 3 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 3 | 3 |
| Motor activity | D009043 | EFO_0003940 | — | — | — | — | — | 3 | 3 |
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 3 | 3 |
| Food diet and nutrition | D000066888 | — | — | — | — | — | — | 2 | 2 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | — | 2 | 2 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 2 | 2 |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | — | — | — | 2 | 2 |
Show 58 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tezacitabine |
| INN | tezacitabine |
| Description | Tezacitabine is a ribonucleotide reductase inhibitor. It is a synthetic purine nucleoside analogue with potential antineoplastic activity. It is used in synthetic DNA.
|
| Classification | Small molecule |
| Drug class | nucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)/C2=C\F)c(=O)n1.O |
Identifiers
| PDB | — |
| CAS-ID | 130306-02-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989496 |
| ChEBI ID | — |
| PubChem CID | 6435808 |
| DrugBank | — |
| UNII ID | 7607Y95N9S (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Docetaxel – Eagle Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 27,673 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cidofovir, Docetaxel, Docetaxel anhydrous, Endrate, Entecavir, Levothyroxine sodium, Osmoprep, Paroxetine hydrochloride anhydrous, Pnv prenatal vitamin, Sodium acetate anhydrous
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
18,927 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use